A
Astex
University of Cambridge spinout, now part of Taiho Oncology, Inc., specializing in fragment-based drug discovery for oncology and CNS disorders
About Astex
Astex Pharmaceuticals specializes in the discovery and development of innovative cancer therapies. The company operates in the biopharmaceutical sector, focusing on creating new drugs to improve patient outcomes. Astex serves major pharmaceutical companies through collaboration and license agreements, contributing to the development of multiple drugs in preclinical and clinical stages. The business model revolves around research and development (R&D) partnerships, where Astex collaborates with leading pharma companies to bring new drugs to market. Revenue is generated through milestone payments, royalties, and licensing fees from these partnerships. The company has successfully brought three approved drugs to market, showcasing its expertise in drug discovery and development. Astex aims to attract and retain talented individuals passionate about improving global health through innovative products and services.
Source: Dealroom company dataAt a glance
- Founded
- 1999
- Headquarters
- Pleasanton, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- UCUniversity of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
104 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Astex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Astex on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.